Biotransformation of the Novel Myeloperoxidase Inhibitor AZD4831 in Preclinical Species and Humans.

导出 OA

翻译打印收藏纠错

作者： Ulrik,Jurva ^[1] ; Lars,Weidolf ^[2] ; Ann-Sofie,Sandinge ^[2] ; Carina,Leandersson ^[2] ; Anja,Ekdahl ^[2] ; Xue-Qing,Li ^[2] ; Thomas,Antonsson ^[2] ; Johan,Sundell ^[2] ; Kristina,Westerlund ^[2] ; Carl,Amilon ^[2] ; Tord,Inghardt ^[2] ; V Sashi,Gopaul ^[2]

作者单位： Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.) ulrik.jurva@astrazeneca.com. ^[1] Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism (U.J., L.W., A-S.S., A.E., X.L., V.S.G.); Drug Metabolism and Pharmacokinetics, Research and Early Development, Respiratory and Immunology (C.L.), Medicinal Chemistry, Research and Early Development, Cardiovascular, Renal and Metabolism (T.A., J.S., K.W., T.I.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; and Formerly of AstraZeneca (L.W., C.A.). ^[2]